Atherogenic apolipoprotein B (apoB)–containing lipoproteins such as low‐density lipoprotein (LDL) and lipoprotein(a) (Lp[a]) have clearly been implicated in the pathogenesis of aortic valve stenosis (AVS).1, 2However, trials aimed at reducing LDL cholesterol (LDL‐C) with statins and ezetimibe have failed to document a significant reduction in AVS progression3 and Lp(a)‐targeted trials have yet to be performed, currently leaving clinicians with no proven medical therapy to reduce disease progression. The gene discussed is APOB; the disease is aortic valve stenosis.